Abstract

Despite the scarcity of the SARS-CoV-2 receptor—human angiotensin-converting enzyme 2 (ACE2)—in the respiratory tract, the omicron variant efficiently infects the respiratory tract, causing rapid and widespread infections of COVID-19. The omicron variant contains extensive mutations in the receptor-binding domain (RBD) of its spike protein that recognizes human ACE2.